• Assessment of hsa_miR502_3p in blood plasma in early stage of Alzheimer's disease
  • Negin Biglari,1 Mohammad Khalaj Kondori,2,*
    1. Dept. of Genetics, Animal Biology Group, Faculty of Natural Science, University of Tabriz, Tabriz, Iran
    2. Dept. of Genetics, Animal Biology Group, Faculty of Natural Science, University of Tabriz, Tabriz, Iran


  • Introduction: MicroRNAs (miRNAs) are short, endogenous, non-coding RNAs that post-transcriptionally regulate gene expression by base pairing with mRNA targets. Altered miRNA expression profiles have been observed in several diseases, including neurodegeneration. Studies have shown that miRNA are involved in many diseases and measuring their expression levels can help in early detection of disease, especially Alzheimer's. By examining 30 patients with Alzheimer's disease and measuring has_mir502_3p, there was a significant relationship between has_mir502_3p expression and Alzheimer's disease.
  • Methods: In this study, Plasma samples were obtained from AD patients and age- and gender-matched controls. total RNA was extracted using the GENEALL extraction kit according to the manufacturer’s protocol. CDNA synthesis was carried out using the PrimeScript II cDNA synthesis kit (Takara, Japan). The expression of the target miRNA and RNU6 as internal control was assessed by Real Time PCR. Data were analyzed by SPSS software and Student's t-test.
  • Results: Studies suggest that altered hsa_miR502_3p expression may be involved in the diagnosis of patients with Alzheimer's disease. Evaluation of hsa-miR502_3P expression is thought to be helpful in early detection of Alzheimer's disease and thus to slow down the course of Alzheimer's disease.
  • Conclusion: Results of this study expect that has_mir502_3p expression might be a potent biomarker for Alzheimer's disease.
  • Keywords: Alzheimer, has_mir502_3p , qRT-PCR , microRNA